Wednesday, 21 October 2026 10:10 AM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / October 21, 2026 / EyePoint Pharmaceuticals (NASDAQ:EYPT) shares fell roughly 80% after the Company reported that its Phase 3 LUCIA trial of DURAVYU in wet age-related macular degeneration missed its primary endpoint of non-inferiority to on-label aflibercept. If you held EYPT shares when that result hit, your losses may be part of an active investigation. Investors who suffered losses are encouraged to submit their EYPT loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
In LUCIA, DURAVYU patients gained approximately 2.5 letters in mean best-corrected visual acuity. Patients receiving on-label aflibercept gained approximately 6.1 letters, a gap of roughly 3.7 letters. DURAVYU is EyePoint's lead pipeline candidate, and LUCIA was one of two pivotal Phase 3 wet AMD trials, alongside LUGANO.
After the LUCIA result, EyePoint announced it would conclude its wet AMD pivotal trials early. It also announced it would cut approximately 53% of its workforce. The Company also expects approximately $9 million in one-time charges. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT investors.
Shareholders who lost money on EyePoint can request a no-cost review of their EYPT losses or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the EYPT Investigation
Q: Who is conducting the EYPT investigation? A: Levi & Korsinsky, LLP is investigating potential securities law claims on behalf of investors who purchased EYPT securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Who is eligible to participate in the EYPT investigation? A: Investors who purchased EYPT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did EYPT stock drop? A: Shares fell roughly 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU in wet AMD missed its primary endpoint of non-inferiority to on-label aflibercept. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What do EYPT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my EYPT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP